Literature DB >> 30690916

Twenty-four-hour motor activity and body temperature patterns suggest altered central circadian timekeeping in Smith-Magenis syndrome, a neurodevelopmental disorder.

Ann C M Smith1, Rebecca S Morse1, Wendy Introne1, Wallace C Duncan2.   

Abstract

Smith-Magenis syndrome (SMS) is a contiguous gene syndrome linked to interstitial microdeletion, or mutation of RAI1, within chromosome 17p11.2. Key behavioral features of SMS include intellectual disability, sleep-disturbances, maladaptive, aggressive and self-injurious behaviors, hyperactivity, and sudden changes in mood. A distinguishing feature of this syndrome is an inverted pattern of melatonin characterized by elevated daytime and low nighttime melatonin levels. As the central circadian clock controls the 24-hr rhythm of melatonin, we hypothesized that the clock itself may contribute to the disrupted pattern of melatonin and sleep. In this report, 24-hr patterns of body temperature, a surrogate marker of clock-timing, and continuous wrist activity were collected to examine the links between body temperature, sleep behavior, and the circadian clock. In addition, age-dependent changes in sleep behavior were explored. Actigraphy-estimated sleep time for SMS was 1 hr less than expected across all ages studied. The timing of the 24-hr body temperature (Tb-24) rhythm was phase advanced, but not inverted. Compared to sibling (SIB) controls, the SMS group had less total night sleep, lower sleep efficiency, earlier sleep onset, earlier final awake times, increased waking after sleep onset (WASO), and increased daytime nap duration. The timing of wake onset varied with age, providing evidence of ongoing developmental sleep changes from childhood through adolescence. Clarification of the circadian and developmental factors that contribute to the disrupted and variable sleep patterns in this syndrome will be helpful in identifying more effective individualized treatments. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  zzm321990RAI1; body temperature; circadian sleep disorder; del 17p11.2; melatonin; neurodevelopmental disorder

Mesh:

Substances:

Year:  2019        PMID: 30690916      PMCID: PMC6699156          DOI: 10.1002/ajmg.a.61003

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  63 in total

1.  Distinctiveness and correlates of maladaptive behaviour in children and adolescents with Smith-Magenis syndrome.

Authors:  E M Dykens; A C Smith
Journal:  J Intellect Disabil Res       Date:  1998-12

Review 2.  Chronobiology and psychiatry.

Authors:  Anna Wirz-Justice
Journal:  Sleep Med Rev       Date:  2007-12       Impact factor: 11.609

Review 3.  Aging in the circadian system: considerations for health, disease prevention and longevity.

Authors:  Erin M Gibson; Wilbur P Williams; Lance J Kriegsfeld
Journal:  Exp Gerontol       Date:  2008-05-23       Impact factor: 4.032

4.  Behavioral sleep problems in children and adolescents.

Authors:  Melisa Moore
Journal:  J Clin Psychol Med Settings       Date:  2012-03

5.  Direct comparison of two new actigraphs and polysomnography in children and adolescents.

Authors:  Lisa J Meltzer; Colleen M Walsh; Joel Traylor; Anna M L Westin
Journal:  Sleep       Date:  2012-01-01       Impact factor: 5.849

Review 6.  Actigraphy and motion analysis: new tools for psychiatry.

Authors:  M H Teicher
Journal:  Harv Rev Psychiatry       Date:  1995 May-Jun       Impact factor: 3.732

7.  RAI1 variations in Smith-Magenis syndrome patients without 17p11.2 deletions.

Authors:  S Girirajan; L J Elsas; K Devriendt; S H Elsea
Journal:  J Med Genet       Date:  2005-03-23       Impact factor: 6.318

8.  A factor analysis of the signs and symptoms of mania.

Authors:  F Cassidy; K Forest; E Murry; B J Carroll
Journal:  Arch Gen Psychiatry       Date:  1998-01

9.  How accurately does wrist actigraphy identify the states of sleep and wakefulness?

Authors:  C P Pollak; W W Tryon; H Nagaraja; R Dzwonczyk
Journal:  Sleep       Date:  2001-12-15       Impact factor: 5.849

10.  Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression.

Authors:  Ying-Hui Wu; Jeanine Ursinus; Jiang-Ning Zhou; Frank A J L Scheer; Bao Ai-Min; Ralf Jockers; Joop van Heerikhuize; Dick F Swaab
Journal:  J Affect Disord       Date:  2013-01-26       Impact factor: 4.839

View more
  5 in total

1.  De Novo KAT5 Variants Cause a Syndrome with Recognizable Facial Dysmorphisms, Cerebellar Atrophy, Sleep Disturbance, and Epilepsy.

Authors:  Jonathan Humbert; Smrithi Salian; Periklis Makrythanasis; Gabrielle Lemire; Justine Rousseau; Sophie Ehresmann; Thomas Garcia; Rami Alasiri; Armand Bottani; Sylviane Hanquinet; Erin Beaver; Jennifer Heeley; Ann C M Smith; Seth I Berger; Stylianos E Antonarakis; Xiang-Jiao Yang; Jacques Côté; Philippe M Campeau
Journal:  Am J Hum Genet       Date:  2020-08-20       Impact factor: 11.025

Review 2.  Circadian disruption and human health.

Authors:  Anna B Fishbein; Kristen L Knutson; Phyllis C Zee
Journal:  J Clin Invest       Date:  2021-10-01       Impact factor: 19.456

3.  Composite Sleep Problems Observed Across Smith-Magenis Syndrome, MBD5-Associated Neurodevelopmental Disorder, Pitt-Hopkins Syndrome, and ASD.

Authors:  Anusha Gandhi; Dihong Zhou; Joseph Alaimo; Edwin Chon; Michael D Fountain; Sarah H Elsea
Journal:  J Autism Dev Disord       Date:  2021-06

Review 4.  Smith-Magenis Syndrome-Clinical Review, Biological Background and Related Disorders.

Authors:  Berardo Rinaldi; Roberta Villa; Alessandra Sironi; Livia Garavelli; Palma Finelli; Maria Francesca Bedeschi
Journal:  Genes (Basel)       Date:  2022-02-11       Impact factor: 4.096

5.  Tasimelteon safely and effectively improves sleep in Smith-Magenis syndrome: a double-blind randomized trial followed by an open-label extension.

Authors:  Christos M Polymeropoulos; Justin Brooks; Emily L Czeisler; Michaela A Fisher; Mary M Gibson; Kailey Kite; Sandra P Smieszek; Changfu Xiao; Sarah H Elsea; Gunther Birznieks; Mihael H Polymeropoulos
Journal:  Genet Med       Date:  2021-07-27       Impact factor: 8.822

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.